A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for HealthResearch (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as ro...

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…This cost was used in the NICE TA101 having been estimated from costing data originally supplied by Sanofi-Aventis on men with hormone-refractory disease. 108 Drug costs used in the base-case analysis were based on prices listed in the British National Formulary (BNF). 111 …”

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

“…A narrative synthesis is presented and, where appropriate, outcomes were synthesised using formal analytic approaches. Full details of the review methods, including the search strategies, are described in the full technical report (Collins et al, 2006).…”

“…This paper presents the systematic review of the effectiveness evidence. A full technical report is available, which also presents the results of the economic evaluation that was conducted alongside the systematic review (Collins et al, 2006).…”

Early economic evaluation ot technologies for emerging interventions to personalize breast cancer treatment

“…The model assumes that the entire affected population will receive the optimal strategy. In the Netherlands the affected population amounts to 662 patients per annum (of the 6619 breast cancer women below 60 years in the Netherlands [46], 20% are expected to be TNBC [28,[47][48][49][50], of these, 30% are stage II-III [51] and 20% are oligometastatic cancers [52] i.e., treatable metastatic cases). To this figure, an annual discount rate of 4% was applied over a 10-year time horizon of the technology, assumed to be the period during which 4 the information is relevant to inform the decision.…”

“…Canada [48] due to the lack of a Dutch estimator, NHS reference costs [27,41,[49][50][51][52][53][54][55][56] and average selling prices from CMS [28] and literature [57][58][59][60][61][62][63] for the US. All costs were inflated to 2013 values using the Consumer Price Index [64] and transformed to Euros [65].…”